Skip to content
HowShorted

Corvus Pharmaceuticals, Inc. short interest in 2022

In 2022, Corvus Pharmaceuticals, Inc.'s disclosed short interest ran from 0.64% of shares outstanding on 14 Jan 2022 to 0.38% on 30 Dec 2022, a change of -0.26 percentage points. The year's high was 0.73% on 15 Feb 2022 and its low 0.32% on 15 Dec 2022, averaging 0.48% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.93 days on 30 Nov 2022. Full history: Corvus Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Corvus Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
0.64% (14 Jan 2022)
End of year
0.38% (30 Dec 2022)
Change
-0.26 pp
High
0.73% (15 Feb 2022)
Low
0.32% (15 Dec 2022)
Average
0.48%
Highest days to cover
4.93 (30 Nov 2022)
SEC filings marked
8

Every report in 2022

Corvus Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20220.64%1.00
31 Jan 20220.36%1.00
15 Feb 20220.73%1.17
28 Feb 20220.43%1.07
15 Mar 20220.44%1.1710-K filed, results (8-K)
31 Mar 20220.46%1.09
14 Apr 20220.39%1.00
29 Apr 20220.42%1.01
13 May 20220.53%1.0410-Q filed, results (8-K)
31 May 20220.41%1.03
15 Jun 20220.49%1.27
15 Aug 20220.71%1.0010-Q filed, results (8-K)
15 Sep 20220.43%1.37
30 Sep 20220.44%1.00
14 Oct 20220.51%1.70
31 Oct 20220.44%1.62
15 Nov 20220.44%1.1810-Q filed, results (8-K)
30 Nov 20220.70%4.93
15 Dec 20220.32%1.00
30 Dec 20220.38%1.70

See also: Corvus Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.